Pomalidomide in the Treatment of Multiple Myeloma: Design, Development and Place in Therapy

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2017 Sep 2

PMID 28860711

Citations 15

Authors

Rafael Rios-Tamayo

Agustin Martin-Garcia

Carolina Alarcon-Payer

Dolores Sanchez-Rodriguez

Ana Maria Del Valle Diaz de la Guardia

Carlos Gustavo Garcia Collado

Alberto Jimenez Morales

Manuel Jurado Chacon

Jose Cabeza Barrera

Affiliations

Soon will be listed here.

Abstract

Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and the widespread use of new agents, patients with relapsed and refractory disease have a poor outcome. Immunomodulatory drugs play a key role in both the front-line and the relapsed/refractory setting. The combination of pomalidomide (POM) and dexamethasone is safe and effective in relapsed and refractory patients, even in those with high-risk cytogenetic features. Furthermore, it can be used in most patients without the need to adjust according to the degree of renal failure. In order to further improve the results, POM-based triplet therapies are currently used. This article highlights the most relevant issues of POM and POM-based combinations in the relapsed/refractory multiple myeloma setting, from a pharmacological and clinical point of view.

Citing Articles

Pomalidomide in patients with multiple myeloma: potential impact on the reconstitution of a functional T-cell immunity.

Shen J, Senes F, Wen X, Monti P, Lin S, Pinna C Immunol Res. 2024; 72(6):1470-1478.

PMID: 39316338 PMC: 11618177. DOI: 10.1007/s12026-024-09546-w.

Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world cohort study in China.

Han X, Jiang X, He J, Zheng G, Xiong Y, Wen Y Cancer Med. 2024; 13(9):e7232.

PMID: 38698679 PMC: 11066492. DOI: 10.1002/cam4.7232.

The real-world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies.

Szabo A, Thorsen J, Iversen K, Levring M, Helleberg C, Hermansen E EJHaem. 2023; 4(4):1006-1012.

PMID: 38024635 PMC: 10660104. DOI: 10.1002/jha2.774.

[The efficacy and safety analysis of pomalidomide in the treatment of relapsed/refractory multiple myeloma].

Lu J, He H, Li L, Qiang W, Liu J, Guo P Zhonghua Xue Ye Xue Za Zhi. 2023; 44(1):75-78.

PMID: 36987729 PMC: 10067371. DOI: 10.3760/cma.j.issn.0253-2727.2023.01.015.

Pomalidomide-induced lung injury: A case report.

Vivien A, Ancel J, Godet S, Dury S, Perotin J, Deslee G Medicine (Baltimore). 2023; 102(2):e32473.

PMID: 36637962 PMC: 9839242. DOI: 10.1097/MD.0000000000032473.

References

Kronke J, Udeshi N, Narla A, Grauman P, Hurst S, McConkey M . Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2013; 343(6168):301-5. PMC: 4077049. DOI: 10.1126/science.1244851. View

Pan B, Lentzsch S . The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacol Ther. 2012; 136(1):56-68. DOI: 10.1016/j.pharmthera.2012.07.004. View

Kumar S, Paiva B, Anderson K, Durie B, Landgren O, Moreau P . International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346. DOI: 10.1016/S1470-2045(16)30206-6. View

Hoffmann M, Kasserra C, Reyes J, Schafer P, Kosek J, Capone L . Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol. 2012; 71(2):489-501. PMC: 3556473. DOI: 10.1007/s00280-012-2040-6. View

Chang X, Zhu Y, Shi C, Stewart A . Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma. Acta Biochim Biophys Sin (Shanghai). 2013; 46(3):240-53. PMC: 4357794. DOI: 10.1093/abbs/gmt142. View

Kumar S, Lee J, Lahuerta J, MORGAN G, Richardson P, Crowley J . Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2011; 26(1):149-57. PMC: 4109061. DOI: 10.1038/leu.2011.196. View

Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan G, Crowley J . Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014; 124(20):3043-51. PMC: 4231416. DOI: 10.1182/blood-2014-07-552059. View

Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I . Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2015; 33(30):3459-66. DOI: 10.1200/JCO.2014.60.2466. View

Anderson K . Progress and Paradigms in Multiple Myeloma. Clin Cancer Res. 2017; 22(22):5419-5427. PMC: 5300651. DOI: 10.1158/1078-0432.CCR-16-0625. View

10.

Rios-Tamayo R, Sanchez M, Puerta J, Sainz J, Chang D, Rodriguez T . Trends in survival of multiple myeloma: a thirty-year population-based study in a single institution. Cancer Epidemiol. 2015; 39(5):693-9. DOI: 10.1016/j.canep.2015.08.002. View

11.

Schey S, Ramasamy K . Pomalidomide therapy for myeloma. Expert Opin Investig Drugs. 2011; 20(5):691-700. DOI: 10.1517/13543784.2011.567265. View

12.

Dimopoulos M, Weisel K, Song K, Delforge M, Karlin L, Goldschmidt H . Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica. 2015; 100(10):1327-33. PMC: 4591765. DOI: 10.3324/haematol.2014.117077. View

13.

Song K, Dimopoulos M, Weisel K, Moreau P, Palumbo A, Belch A . Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma. Haematologica. 2014; 100(2):e63-7. PMC: 4803120. DOI: 10.3324/haematol.2014.112557. View

14.

Larocca A, Montefusco V, Bringhen S, Rossi D, Crippa C, Mina R . Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood. 2013; 122(16):2799-806. DOI: 10.1182/blood-2013-03-488676. View

15.

Jones J, Pawlyn C, Davies F, Morgan G . The safety of pomalidomide for the treatment of multiple myeloma. Expert Opin Drug Saf. 2016; 15(4):535-47. DOI: 10.1517/14740338.2016.1154039. View

16.

Usmani S, Rodriguez-Otero P, Bhutani M, Mateos M, Miguel J . Defining and treating high-risk multiple myeloma. Leukemia. 2015; 29(11):2119-25. DOI: 10.1038/leu.2015.209. View

17.

Terpos E, Kanellias N, Christoulas D, Kastritis E, Dimopoulos M . Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. Onco Targets Ther. 2013; 6:531-8. PMC: 3656921. DOI: 10.2147/OTT.S34498. View

18.

Rajkumar S . Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016; 91(7):719-34. PMC: 5291298. DOI: 10.1002/ajh.24402. View

19.

Richardson P, Siegel D, Vij R, Hofmeister C, Baz R, Jagannath S . Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014; 123(12):1826-32. PMC: 3962162. DOI: 10.1182/blood-2013-11-538835. View

20.

Wang M, Dimopoulos M, Chen C, Cibeira M, Attal M, Spencer A . Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 2008; 112(12):4445-51. DOI: 10.1182/blood-2008-02-141614. View